Pathway Pharmaceuticals Company

Pathway Pharmaceuticals combined contemporary techniques in genetics, systems biology, bioinformatics and molecular biology and created an original ground breaking technology to discover the most effective available treatment plan that pertains to each patient’s particular case. It is the sole company currently undertaking such exclusive molecular analysis of patients’ tissue samples consisting of profiling complete transcriptome, analyzing affected intracellular molecular signaling pathways and finding the best target therapeutics that may efficiently stop cancer progression in each case of individual patient’s tumor. Furthermore, Pathway Pharmaceuticals remains the only company that offers a complete analysis of clinical trials databases focused on the case of the individual patient, which sufficiently increases the success of therapy. The knowledge and skills of Pathway Pharmaceuticals board-certified medical review committee is the driving force of the whole diagnostic method. With the most modern technology, Pathway Pharmaceuticals can incorporate each patient’s tumor molecular assessment with his actual past medical history, to develop specific treatment strategy for each patient. The company engages top professionals in the field to constantly update and enhance its technological basis. In conclusion, Pathway Pharmaceuticals customized report in a creative manner merges together the medical history and the results of the molecular profiling, which leads to recommendation of certain target anticancer drugs. The procedure is fully user-friendly and offers multiple options which allow identification of the most effective treatment plan for each cancer patient individually.
Technology: other
Industry: Biotechnology, Health Care, Medical
Headquarters: Hong Kong
Founded Date: 41640
Employees Number: 11-50
Funding Status: Seed
Estimated Revenue: $1M to $10M
Last Funding Date: 2015-08-25
Last Funding Type: Seed

Visit Website
Register and Claim Ownership